The Alliance for Regenerative Medicine and 13 biotech companies released a statement outlining bioethical principles on genome editing, including opposition to modifications that can be passed to future generations.
One of the four sites of the trial, in a rare form of inherited blindness, is currently listed as open for enrollment, and the companies plan to dose the first patient soon.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Shares of gene-editing companies were down Tuesday morning following the news, but analysts sought to reassure investors about Editas.
The decision in favor of Broad Institute of MIT and Harvard by a panel of judges at the US Court of Appeals for the Federal Circuit leaves UC Berkeley with few options to appeal further.
FDA slaps clinical hold on Crispr Therapeutics and Vertex Pharmaceuticals' upcoming gene-editing trial.
Gene editing offers near-limitless medical potential. The challenge is putting it into medical practice. So how is gene editing progressing, in terms of biotech pipelines, investment, and therapeutic approvals?
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The hot gene editing company plans to raise a comparatively small amount of money in its IPO, when considering the amount of money it's raised privately.
CRISPR gene editing is heralded one of the most promising technologies today - and it's ramping up fast. Here's a commercial timeline - from just the past year.
Looks like the gene editing startup plans to start with simple gene editing techniques that focus heavily on diseases of the eye.
Looks like CRISPR is headed to the clinic: Editas Medicine just announced that it'll bring this gene editing technology to human trials by 2017.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The market potential of CRISPR technology has been legitimized by Editas Medicine's impressive, $120 million fundraise. Here are six more biotechs shaping the CRISPR landscape look like now? And what other players are in this game?
Isn't Theranos supposed to be a smart company? The MIT Technology Review highlights each year what it considers the world's "smartest companies." Understandably, several have been left out.
An NIH study has shown that giving HIV drugs when patients are initially diagnosed with the disease is more effective than waiting for the white blood cell counts to drop.